$PYPD Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.35 up 55.13% YoY
• PolyPid expects to submit a Marketing Authorization Application to the European Medicines Agency during the third quarter of 2026, with a potential U.S. commercial launch of D-PLEX100 targeted for early 2027.